Regeneron Pharmaceuticals Set to Report Q1 Earnings Amid Mixed Market Trends
Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalization of $62.4 billion and focuses on discovering, inventing, developing, manufacturing, and commercializing medicines for a variety of diseases globally. Based in Tarrytown, New York, Regeneron’s product lineup includes EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara.
Upcoming Earnings Report and Analyst Expectations
The company is scheduled to report its Q1 earnings on Tuesday, April 29, before the market opens. Analysts anticipate REGN will post an earnings per share (EPS) of $7, reflecting a 12.2% decrease from the $7.97 reported in the same quarter last year. In the prior four quarters, Regeneron exceeded analysts’ earnings expectations in three instances, while only missing in one. The recent quarter showcased an EPS of $9.90, which surpassed estimates by 2.9%, fueled by increased sales of Dupixent, EYLEA HD, EYLEA, and Libtayo.
Future Earnings Projections
Looking ahead to fiscal 2025, analysts expect Regeneron to report an adjusted EPS of $32.72, down 15.3% from $38.62 in fiscal 2024. However, fiscal 2026 predictions indicate a 9.2% increase in adjusted EPS, projected at $35.72.
Stock Performance and Market Context
Over the past year, REGN shares have dropped 37.9%, significantly trailing the S&P 500 Index’s ($SPX) gains of 6.6% and the Health Care Select Sector SPDR Fund’s (XLV) slight decline during the same period.
On April 8, REGN stock fell more than 2% along with other pharmaceutical and drug manufacturing stocks after President Trump announced that the U.S. would implement “a major tariff” on the industry soon. This came despite wider market recoveries following Trump’s announcement of a temporary halt to most reciprocal tariffs; pharmaceutical and healthcare stocks have faced challenges recently.
Analyst Ratings and Market Sentiment
The consensus stance on REGN stock is notably positive, reflected in an overall “Strong Buy” rating. From 25 analysts monitoring the stock, 18 recommend a “Strong Buy,” one suggests a “Moderate Buy,” five advise a “Hold,” and one proposes a “Moderate Sell.” The mean price target currently sits at $927.08, suggesting a substantial 67.2% upside potential from existing price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
